| Bothell, WA., June 28 -- Lumera Corporation (NASDAQ:LMRA),
a leader in the emerging field of nanotechnology, announced today
that it has been invited to demonstrate its ProteomicProcessor™ Biosensor
at the 2006 Proteomics course at Cold Spring Harbor Laboratory.
As one of eight National Cancer Institute-designated basic research
centers in the U.S., Cold Spring Harbor hosts a series of short
courses whereby academic and industrial scientists gather to learn
the latest scientific advances and to be trained in new cutting
edge technologies.
“
We are both excited and grateful for the opportunity to have our
instrument platform included in this event,” said Tom Mino,
Lumera CEO. “While this event gives us exposure to additional
academic accounts, it also raises our profile in the pharmaceutical
industry. Scientists from large pharmaceutical companies will have
the opportunity to see our technology first hand.”
Lumera has begun presales activities for its ProteomicProcessor™ platform
in anticipation of the product launch in the fourth quarter. In
addition to the demonstration at Cold Spring Harbor, Lumera is
ramping their sales and marketing activities which include a focus
group of therapeutic antibody companies, presentations at leading
biotechnology and pharmaceutical companies, and product presentation
at leading conferences. In anticipation of the fourth quarter product
launch, the company has begun to increase sales and marketing personnel,
recently adding an Applications Scientist to support the growing
user base.
About Lumera
Lumera is a leader in the emerging field of nanotechnology. The
company designs proprietary molecular structures and polymer compounds
for the bioscience and communications/computing industries, both
of which represent large market opportunities. The company also
has developed proprietary processes for fabricating such devices.
For more information, please visit www.lumera.com.
About Cold Spring Harbor Laboratory
The Proteomics course at Cold Spring Harbor Laboratory (http://meetings.cshl.edu/courses/c-proteo06.shtml)
is a three week intensive laboratory and lecture course focusing
on two major themes in proteomics: protein profiling and functional
proteomics. The course receives financial support from the Nation
Cancer Institute and features world renowned instructors from academics
and industry.
Cold Spring Harbor Laboratory is a private, non-profit basic research
and educational institution. Under the leadership of Dr. Bruce
Stillman, a member of the National Academy of Sciences and a Fellow
of the Royal Society (London), some 400 scientists conduct groundbreaking
research there in cancer, neurobiology, plant genetics and bioinformatics.
Cold Spring Harbor Laboratory is one of eight National Cancer Institute-designated
basic research centers in the U.S. and the only such center in
the tri-state area.
Certain statements contained in this release are forward-lookingstatements
that involve a number of risks and uncertainties. Factorsthat could
cause actual results to differ materially from thoseprojected in
the company's forward-looking statements include thefollowing:
market acceptance of our technologies and products; ourability
to obtain financing; our financial and technical resourcesrelative
to those of our competitors; our ability to keep up withrapid technological
change; government regulation of our technologies;our ability to
enforce our intellectual property rights and protectour proprietary
technologies; the ability to obtain additionalcontract awards and
to develop partnership opportunities; the timingof commercial product
launches; the ability to achieve key technicalmilestones in key
products; and other risk factors identified fromtime to time in
the company's SEC reports, including its Annual Reporton Form 10-K,
and its Quarterly Reports on Form 10-Q.
|
